The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence

References

• Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA, USA (2011).
   Google Scholar
• Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension33(5), 1130–1134 (1999).
   PubMed Web of Science ®Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract.87(1), 4–14 (2010).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet365(9455), 217–223 (2005).
   PubMed Web of Science ®Google Scholar
• Wong ND, Lopez VA, L’Italien G et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch. Intern. Med.167(22), 2431–2436 (2007).
   PubMed Web of Science ®Google Scholar
• Eguchi K, Pickering TG, Kario K. Why is blood pressure so hard to control in patients with Type 2 diabetes? J. Cardiometab. Syndr.2(2), 114–118 (2007).
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42(6), 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care34(Suppl. 1), S11–S61 (2011).
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens.27, 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Basile J. New therapeutic options in patients prone to hypertension: a focus on direct renin inhibition and aldosterone blockade. Am. J. Med. Sci.337(6), 438–444 (2009).
   Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med.345(12), 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med.345(12), 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med.345(23), 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342(3), 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Appel LJ, Wright JT Jr, Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N. Engl. J. Med.363(10), 918–929 (2010).
   PubMed Web of Science ®Google Scholar
• Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med.148(1), 30–48 (2008).
   PubMed Web of Science ®Google Scholar
• Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet. Med.24(5), 486–493 (2007).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358(15), 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Cowan BR, Young AA, Anderson C et al. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). Am. J. Cardiol.104(11), 1484–1489 (2009).
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet372(9638), 547–553 (2008).
   PubMed Web of Science ®Google Scholar
• Tobe SW, Clase CM, Gao P et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation123(10), 1098–1107 (2011).
   PubMed Web of Science ®Google Scholar
• Vergaro G, Emdin M, Iervasi A et al. Prognostic value of plasma renin activity in heart failure. Am. J. Cardiol.108(2), 246–251 (2011).
   PubMedGoogle Scholar
• Verma S, Gupta M, Holmes DT et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur. Heart J.32(17), 2135–2142 (2011).
   Google Scholar
• Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM et al. The renin–angiotensin system and diabetes: an update. Vasc. Health Risk Manag.4(4), 787–803 (2008).
   PubMedGoogle Scholar
• Atlas SA. The renin–angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J. Manag. Care Pharm.13(8 Suppl. SB), S9–S20 (2007).
   PubMed Web of Science ®Google Scholar
• Steckelings UM, Rompe F, Kaschina E, Unger T. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam. Clin. Pharmacol.23(6), 693–703 (2009).
   PubMed Web of Science ®Google Scholar
• Strain WD, Chaturvedi N. The renin–angiotensin–aldosterone system and the eye in diabetes. J. Renin Angiotensin Aldosterone Syst.3(4), 243–246 (2002).
   Web of Science ®Google Scholar
• Lai KN, Leung JC, Lai KB et al. Gene expression of the renin–angiotensin system in human kidney. J. Hypertens.16(1), 91–102 (1998).
   PubMedGoogle Scholar
• Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension46(5), 1069–1076 (2005).
   PubMed Web of Science ®Google Scholar
• Toma I, Kang JJ, Sipos A et al. Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J. Clin. Invest.118(7), 2526–2534 (2008).
   PubMed Web of Science ®Google Scholar
• Colucci JA, Arita DY, Cunha TS et al. Renin–angiotensin system may trigger kidney damage in NOD mice. J. Renin Angiotensin Aldosterone Syst.12(1), 15–22 (2011).
   Google Scholar
• Bonnet F, Candido R, Carey RM et al. Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin Type 1 receptor blockade. J. Hypertens.20(8), 1615–1624 (2002).
   PubMed Web of Science ®Google Scholar
• Reinemund J, Seidel K, Steckelings UM et al. Poly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally regulates angiotensin AT2 receptor (AT2R) and AT2R binding protein (ATBP) genes. Biochem. Pharmacol.77(12), 1795–1805 (2009).
   Google Scholar
• Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes57(12), 3297–3306 (2008).
   PubMed Web of Science ®Google Scholar
• Singh VP, Baker KM, Kumar R. Activation of the intracellular renin–angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am. J. Physiol. Heart Circ. Physiol.294(4), H1675–H1684 (2008).
   Google Scholar
• Saris JJ, ‘t Hoen PA, Garrelds IM et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension48(4), 564–571 (2006).
   PubMed Web of Science ®Google Scholar
• Lavrentyev EN, Malik KU. High glucose-induced Nox1-derived superoxides downregulate PKC-βII, which subsequently decreases ACE2 expression and ANG(1–7) formation in rat VSMCs. Am. J. Physiol. Heart Circ. Physiol.296(1), H106–H118 (2009).
   Google Scholar
• Ebrahimian TG, Tamarat R, Clergue M et al. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in Type 1 diabetic mice. Arterioscler. Thromb. Vasc. Biol.25(1), 65–70 (2005).
   PubMed Web of Science ®Google Scholar
• Nguyen G, Delarue F, Burckle C et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest.109(11), 1417–1427 (2002).
   PubMed Web of Science ®Google Scholar
• Ichihara A, Sakoda M, Kurauchi-Mito A, Kaneshiro Y, Itoh H. Renin, prorenin and the kidney: a new chapter in an old saga. J. Nephrol.22(3), 306–311 (2009).
   Google Scholar
• Siragy HM, Huang J. Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity. Exp. Physiol.93(5), 709–714 (2008).
   PubMed Web of Science ®Google Scholar
• Matavelli LC, Huang J, Siragy HM. (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin. Exp. Pharmacol. Physiol.37(3), 277–282 (2010).
   PubMed Web of Science ®Google Scholar
• Huang J, Matavelli LC, Siragy HM. Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-b1-connective tissue growth factor signalling cascade. Clin. Exp. Pharmacol. Physiol.38(4), 215–221 (2011).
   Google Scholar
• Ichihara A, Hayashi M, Kaneshiro Y et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the ‘handle’ region for nonproteolytic activation of prorenin. J. Clin. Invest.114(8), 1128–1135 (2004).
   PubMed Web of Science ®Google Scholar
• Uddin MN, Nabi AH, Nakagawa T et al. Non-proteolytic activation of prorenin: activation by (pro)renin receptor and its inhibition by a prorenin prosegment, ‘decoy peptide’. Front. Biosci.13, 745–753 (2008).
   Google Scholar
• Feldt S, Maschke U, Dechend R, Luft FC, Muller DN. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J. Am. Soc. Nephrol.19(4), 743–748 (2008).
   PubMed Web of Science ®Google Scholar
• Muller DN, Klanke B, Feldt S et al. (Pro)renin receptor peptide inhibitor ‘handle-region’ peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension51(3), 676–681 (2008).
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin–angiotensin–aldosterone system blockade: is oral renin inhibition the solution? Expert Opin. Pharmacother.8(5), 529–535 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrario CM. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin–angiotensin–aldosterone system: antihypertensive effects and benefits beyond BP control. Life Sci.86(9–10), 289–299 (2010).
   Google Scholar
• Azizi M. Direct renin inhibition: clinical pharmacology. J. Mol. Med.86(6), 647–654 (2008).
   PubMedGoogle Scholar
• Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation117(25), 3199–3205 (2008).
   PubMed Web of Science ®Google Scholar
• Uresin Y, Taylor AA, Kilo C et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin Angiotensin Aldosterone Syst.8(4), 190–198 (2007).
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Reinhard H et al. Renal effects of aliskiren compared to and in combination with irbesartan in patients with Type 2 diabetes, hypertension and albuminuria. Diabetes Care32(10), 1873–1879 (2009).
   PubMed Web of Science ®Google Scholar
• Feldman DL, Jin L, Xuan H et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension52(1), 130–136 (2008).
   PubMed Web of Science ®Google Scholar
• Durvasula RV, Shankland SJ. Activation of a local renin angiotensin system in podocytes by glucose. Am. J. Physiol. Renal Physiol.294(4), F830–F839 (2008).
   Web of Science ®Google Scholar
• Sakoda M, Ichihara A, Kurauchi-Mito A et al. Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes. Am. J. Hypertens.23(5), 575–580 (2010).
   Google Scholar
• Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia50(11), 2398–2404 (2007).
   PubMed Web of Science ®Google Scholar
• Dong YF, Liu L, Lai ZF et al. Aliskiren enhances protective effects of valsartan against Type 2 diabetic nephropathy in mice. J. Hypertens.28(7), 1554–1565 (2010).
   PubMed Web of Science ®Google Scholar
• Kang YS, Lee MH, Song HK et al. Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol. Dial. Transplant.26(4), 1194–1204 (2011).
   Google Scholar
• Dong YF, Liu L, Kataoka K et al. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and Type 2 diabetes. Diabetologia53(1), 180–191 (2010).
   PubMed Web of Science ®Google Scholar
• Iwai M, Kanno H, Tomono Y et al. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in Type 2 diabetic KK-A(y) mice. J. Hypertens.28(7), 1471–1481 (2010).
   Google Scholar
• Scheen AJ. Renin–angiotensin system inhibition prevents Type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab.30(6), 498–505 (2004).
   PubMed Web of Science ®Google Scholar
• Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect? Curr. Opin. Pharmacol.7(2), 140–145 (2007).
   PubMed Web of Science ®Google Scholar
• Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Armin DH. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with Type 2 diabetes mellitus. Clin. Pharmacokinet.45(11), 1125–1134 (2006).
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Maboudian M, Warren V et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Curr. Med. Res. Opin.24(8), 2313–2326 (2008).
   PubMed Web of Science ®Google Scholar
• Townsend RR, Forker A, Rumpelt P, Papst CC, Yadao A. Initial combination therapy with aliskiren/hydrochlorothiazide is more effective than amlodipine in patients with stage 2 systolic hypertension and diabetes mellitus. J. Clin. Hypertens.12(7), 534 (2010) (Abstract LB-PO-03).
   Google Scholar
• Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med.358(23), 2433–2446 (2008).
   PubMed Web of Science ®Google Scholar
• Persson F, Lewis JB, Lewis EJ et al. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with Type 2 diabetes and nephropathy. Clin. J. Am. Soc. Nephrol.6(5), 1025–1031 (2011).
   PubMed Web of Science ®Google Scholar
• Persson F, Lewis JB, Lewis EJ et al. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with Type 2 diabetes and nephropathy. Diabetes Care33(11), 2304–2309 (2010).
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Schjoedt KJ et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in Type 2 diabetes. Kidney Int.73(12), 1419–1425 (2008).
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Reinhard H et al. Optimal antiproteinuric dose of aliskiren in Type 2 diabetes mellitus: a randomised crossover trial. Diabetologia53(8), 1576–1580 (2010).
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Lai V, Scholey JW et al. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated Type 1 diabetes: a pilot study. Diabetes Care33(2), 361–365 (2010).
   PubMed Web of Science ®Google Scholar
• Pool JL, Schmieder RE, Azizi M et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am. J. Hypertens.20(1), 11–20 (2007).
   PubMed Web of Science ®Google Scholar
• Solomon SD, Hee SS, Shah A et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur. Heart J.32(10), 1227–1234 (2011).
   PubMed Web of Science ®Google Scholar
• Danser AH. The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor? Hypertens. Res.33(1), 4–10 (2010).
   Google Scholar
• Stanton AV, Gradman AH, Schmieder RE et al. Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials. Hypertension55(1), 54–60 (2010).
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant.24(5), 1663–1671 (2009).
   PubMed Web of Science ®Google Scholar
• Delea TE, Sofrygin O, Palmer JL et al. Cost–effectiveness of aliskiren in Type 2 diabetes, hypertension, and albuminuria. J. Am. Soc. Nephrol.20(10), 2205–2213 (2009).
   PubMed Web of Science ®Google Scholar
• Bader M. Tissue renin–angiotensin–aldosterone systems: targets for pharmacological therapy. Annu. Rev. Pharmacol. Toxicol.50, 439–465 (2010).
   PubMed Web of Science ®Google Scholar